<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01318421</url>
  </required_header>
  <id_info>
    <org_study_id>ELND002-MS153</org_study_id>
    <nct_id>NCT01318421</nct_id>
  </id_info>
  <brief_title>A Study of ELND002 in Patients With Relapsing Forms of Multiple Sclerosis</brief_title>
  <official_title>An Open-Label, Long-Term, Follow-Up Study of Subcutaneous ELND002 in Patients With Relapsing Forms of Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elan Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the long-term safety and tolerability of ELND002 in
      patients with multiple sclerosis (MS) after participation in study MS103.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2010</start_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the safety and tolerability of ELND002 including the identification of dose-limiting toxicity(ies) (DLT).</measure>
    <time_frame>1 year</time_frame>
    <description>Safety and tolerability will be assessed by frequency and severity of AEs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the PK/PD/BM measurement of ELND002 in patients with MS.</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement of drug concentration, alpha 4 receptor saturation, soluble VCAM and MADCAM.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>ELND002</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ELND002 sc injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ELND002</intervention_name>
    <arm_group_label>ELND002</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  This study is open only to subjects who have completed the week 12 visit in study
             ELND002-MS103 while taking their assigned dose of study drug.

        Exclusion Criteria:

          -  Subject has no new medical contraindications to continue participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2011</study_first_submitted>
  <study_first_submitted_qc>March 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2011</study_first_posted>
  <last_update_submitted>December 10, 2015</last_update_submitted>
  <last_update_submitted_qc>December 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsing forms of secondary progressive multiple sclerosis (SPMS)or relapsing-remitting multiple sclerosis (RRMS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

